BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB: IXSBF) (TSX VENTURE: IXS) (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, begins LABapprentice, a competitive summer intern program with a twist, to reach internet surfers via the website: www.labapprentice.com.
